Olaparib pretreatment of IDH-mutant MDS or AML cells displayed a marked reduction of their engraftment capacity, thus suggesting an inhibitory effect of PARP inhibitors on leukemic-initiating cells [177]. The gene discussed is IDH2; the disease is myelodysplastic syndrome.